{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:38:18Z","timestamp":1762868298909,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.suronc.2020.09.019","type":"journal-article","created":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T13:51:59Z","timestamp":1601301119000},"page":"441-446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["HIPEC plus EPIC paclitaxel for maximal perioperative treatments of advanced epithelial ovarian cancer. Long-term results of a pilot study"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2431-7366","authenticated-orcid":false,"given":"Paul H.","family":"Sugarbaker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. Anthony","family":"Stuart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.suronc.2020.09.019_bib1","series-title":"Cytoreductive Surgery & Perioperative Chemotherapy for Peritoneal Surface Malignancy. Textbook and Video Atlas","first-page":"1","article-title":"An overview of peritonectomy, visceral resections, and perioperative chemotherapy for peritoneal surface malignancy","author":"Sugarbaker","year":"2012"},{"key":"10.1016\/j.suronc.2020.09.019_bib2","series-title":"Cytoreductive Surgery & Perioperative Chemotherapy for Peritoneal Surface Malignancy. Textbook and Video Atlas","first-page":"159","article-title":"Pharmacology of perioperative cancer chemotherapy","author":"Van der Speeten","year":"2012"},{"key":"10.1016\/j.suronc.2020.09.019_bib3","first-page":"1545","article-title":"Cancer of the ovary: a summary of experience with cisdichlorodiammineplatinum(II) at the Royal Marsden Hospital","volume":"63","author":"Wiltshaw","year":"1979","journal-title":"Canc. Treat Rep."},{"key":"10.1016\/j.suronc.2020.09.019_bib4","first-page":"706","article-title":"Optimization of intraperitoneal chemotherapy with regional hyperthermia","volume":"27","author":"Los","year":"1991","journal-title":"Eur. J. Canc."},{"issue":"9","key":"10.1016\/j.suronc.2020.09.019_bib5","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.1992.10.9.1485","article-title":"Phase I trial of intraperitoneal taxol: a Gynecologic Oncology Group study","volume":"10","author":"Markman","year":"1992","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.suronc.2020.09.019_bib6","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1055-3207(03)00038-3","article-title":"Intraperitoneal taxanes","volume":"12","author":"Mohamed","year":"2003","journal-title":"Surg. Oncol. Clin."},{"issue":"1","key":"10.1016\/j.suronc.2020.09.019_bib7","first-page":"49","article-title":"Current methodologies for clinical assessment of patients with peritoneal carcinomatosis","volume":"15","author":"Jacquet","year":"1996","journal-title":"J. Exp. Clin. Canc. Res."},{"key":"10.1016\/j.suronc.2020.09.019_bib8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/bjs.4862","article-title":"Systematic review of the Sugarbaker procedure for pseudomyxoma peritonei","volume":"92","author":"Bryant","year":"2005","journal-title":"Br. J. Surg."},{"issue":"3","key":"10.1016\/j.suronc.2020.09.019_bib9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1053\/ejso.2002.1397","article-title":"A comparison of hetastarch and peritoneal dialysis solution for intraperitoneal chemotherapy delivery","volume":"29","author":"Mohamed","year":"2003","journal-title":"Eur. J. Surg. Oncol."},{"issue":"5","key":"10.1016\/j.suronc.2020.09.019_bib10","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1245\/ASO.2006.03.079","article-title":"Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy","volume":"13","author":"Sugarbaker","year":"2006","journal-title":"Ann. Surg Oncol."},{"key":"10.1016\/j.suronc.2020.09.019_bib11","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0378-4347(98)00566-0","article-title":"Rapid and sensitive determination of paclitaxel concentration in mouse plasma by high performance liquid chromatography","volume":"724","author":"Lee","year":"1999","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"key":"10.1016\/j.suronc.2020.09.019_bib12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.suronc.2020.09.019_bib13","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.suronc.2020.09.019_bib14","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2014.55.9898","article-title":"Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a Gynecologic Oncology Group study","volume":"33","author":"Tewari","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.suronc.2020.09.019_bib15","first-page":"1041","article-title":"Role of mathematical modeling in protocol formulation in cancer chemotherapy","volume":"69","author":"Coldman","year":"1985","journal-title":"Canc. Treat Rep."},{"issue":"1","key":"10.1016\/j.suronc.2020.09.019_bib16","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1080\/02656736.2018.1503346","article-title":"Upfront HIPEC and bevacizumab-containing chemotherapy in advanced epithelial ovarian cancer","volume":"35","author":"Paris","year":"2018","journal-title":"Int. J. Hyperther."},{"key":"10.1016\/j.suronc.2020.09.019_bib17","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ygyno.2012.09.020","article-title":"Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two year follow-up","volume":"127","author":"Fagotti","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.suronc.2020.09.019_bib18","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.ejso.2020.01.035","article-title":"Salvage lymphadenectomy in recurrent ovarian cancer patients: analysis of clinical outcome and BRCA1\/2 gene mutational status","volume":"46","author":"Gallotta","year":"2020","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.suronc.2020.09.019_bib19","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIc or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"15_suppl","key":"10.1016\/j.suronc.2020.09.019_bib20","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.5516","article-title":"Survival analyses from a randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer with high tumor load (SCORPION trial)","volume":"36","author":"Fagotti","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.suronc.2020.09.019_bib21","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.clon.2018.04.006","article-title":"When should surgery be used for recurrent ovarian carcinoma?","volume":"30","author":"Bommert","year":"2018","journal-title":"Clin. Oncol."},{"issue":"19","key":"10.1016\/j.suronc.2020.09.019_bib22","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","article-title":"Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial","volume":"36","author":"Ishigami","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.suronc.2020.09.019_bib23","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/SLA.0000000000001705","article-title":"Multicenter phase II study of intravenous and intraperitoneal paclitaxel with S-1 for pancreatic ductal adenocarcinoma patients with peritoneal metastasis","volume":"265","author":"Satoi","year":"2017","journal-title":"Ann. Surg."},{"key":"10.1016\/j.suronc.2020.09.019_bib24","unstructured":"Yamada S, Fujii T, Yamamoto T, et al. Multicenter Phase I\/II Study of Intravenous Gemcitabine + Nab-Paclitaxel Combined with Intraperitoneal Paclitaxel for Patients with Pancreatic Ductal Adenocarcinoma and Peritoneal Metastasis.(submitted)."},{"key":"10.1016\/j.suronc.2020.09.019_bib25","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.suronc.2020.01.009","article-title":"Unusually favorable outcome of 6 consecutive patients with diffuse malignant peritoneal mesothelioma treated with intraperitoneal paclitaxel","volume":"33","author":"Sugarbaker","year":"2020","journal-title":"Surg Oncol"}],"container-title":["Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960740420304023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960740420304023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T03:22:00Z","timestamp":1760757720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960740420304023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":25,"alternative-id":["S0960740420304023"],"URL":"https:\/\/doi.org\/10.1016\/j.suronc.2020.09.019","relation":{},"ISSN":["0960-7404"],"issn-type":[{"type":"print","value":"0960-7404"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HIPEC plus EPIC paclitaxel for maximal perioperative treatments of advanced epithelial ovarian cancer. Long-term results of a pilot study","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.suronc.2020.09.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}